Showing 101 results
Through our ongoing partnership with the Movember Foundation, we have been able to fund the following groundbreaking projects which will lead to clinical trials of better treatments.
Funded research by Dr Chris Parker of the Institute of Cancer Research which looks to develop a risk assessment tool to give a better indication of a man’s risk of having aggressive prostate cancer.
Through our ongoing partnership with the Movember Foundation, we have been able to fund another bumper round of high quality Project and Pilot grants.
Funded research by Dr Jason Webber of Cardiff University which looks at identifying novel exosomal molecules essential for tumour growth, which are present in blood, as indicators of aggressive disease.
Dr Sharp aims to identify proteins that bind to altered versions of the androgen receptor, and investigate whether blocking their activity can hinder cancer progression.
Funded research by Dr Anita Grigoriadis of King's College London looking at finding DNA markers to identify men whose prostate cancer does not need treatment and can be managed by surveillance alone.
Dr Feber and his team aim to improve the way that prostate cancer is diagnosed and monitored. They’ve developed a test that looks at prostate cancer specific DNA modifications that can be detected in the blood of men with prostate cancer.
By assessing how tumour cells repair their DNA, Dr Mateo aims to develop a tool that can identify those patients with a poor prognosis who may benefit from a new treatment.
Funded research by Dr Gerhardt Attard of the Institute of Cancer Research into a simple blood test that will determine the treatment that’s most likely to work for men with advanced hormone-resistant prostate cancer.
Dr Clarkson and his team will test the ability of a new drug developed in their lab to kill prostate cancer stem cells. Dr Clarkson believes that these are the cells responsible for driving cancer spread even after surgery or radiotherapy in men with high-risk localised prostate cancers.
This project aims to develop and test a brand new class of drug that works by disrupting the genetic instructions produced by a cancer promoting gene that’s inappropriately activated in over 50 per cent of prostate cancers.
Dr Zwacka and his team will look into how well, and how safely, a cancer-killing protein loaded into adult stem cells can infiltrate and kill prostate cancer cells in the main prostate tumour and elsewhere in the body.
This project looks into whether bacteria may be involved in prostate cancer development thus presenting opportunities to halt or prevent cancer development through the use of antibiotics.
This project looks into how patients respond to therapy with the aim of matching each individual patient to the best available treatment.
This project looks to develop a tool to work out which men need additional radiotherapy treatment for cancer that has spread outside the prostate to the pelvic lymph nodes.
Funded research by Dr Jonathan Coulter of Queens University Belfast investigating the use of a reactive oxygen species to damage the cancer cell membrane.
Funded research by Dr Luke Gaughan of Newcastle University which looks to understand how different forms of the androgen receptor are regulated in advanced prostate cancer.
Funded research by Dr Justin Sturge of Hull University to assess prostate cancer aggressiveness and give an early indication of whether treatment is necessary.
Funded research by Professor Hing Leung of the University of Glasgow which looks at whether adding statins to hormone treatment will improve treatment response in hormone resistant disease, and whether any new tests can track how well the cancer is responding to treatment.
Funded research by Dr Dow-Mu Koh of Royal Marsden Hospital which looks to test whether a technique called whole body diffusion weighted imaging is a reliable method of how well patients with advanced prostate cancer, who have been treated with olaparib, are responding to treatment.